BRAF and neoplasm: After progression to first-line immunotherapy in MSI-H, we prefer to offer a second-line doublet (fluoropyrimidine with irinotecan or oxaliplatin) with bevacizumab if raf murine sarcoma viral oncogene homolog B1 (BRAF) wild-type, especially if rat sarcoma (RAS) mutated or right-sided tumours.